Video

Dr. Stinchcombe on the KEYNOTE-189 Trial in Lung Cancer

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the KEYNOTE-189 trial in patients with lung cancer.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the KEYNOTE-189 trial in patients with lung cancer.

The KEYNOTE-189 trial builds upon cohort G of the KEYNOTE-21 trial, which was a phase II trial that randomized patients to carboplatin/pemetrexed alone or carboplatin/pemetrexed with pembrolizumab (Keytruda). The phase II trial showed a robust response rate, progression-free survival (PFS), and a trend toward overall survival (OS). According to Stinchcombe, the phase III trial met the statistically significant improvement in PFS and OS. This serves as a confirmatory study to the promising results observed in the phase II trial.

In the experimental arm, patients received pembrolizumab at a 200 mg fixed dose every 3 weeks plus 500 mg/m2 of pemetrexed plus either 75 mg/m2 of cisplatin or carboplatin on day 1 every 3 weeks for 4 cycles, followed by 200 mg of pembrolizumab plus 500 mg/m2 of pemetrexed every 3 weeks. The regimen administered to the control group was identical, except that pembrolizumab was replaced with placebo.

As for other combinations being developed with immunotherapy, the one that is furthest in development is the trial of carboplatin, paclitaxel, and bevacizumab (Avastin) alone or with atezolizumab (Tecentriq). This comparison was seen in a 3-arm trial showing promising improvement in response and a statistically significant improvement in PFS. The OS data are immature at this time.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity